2021-08-012024-05-17https://scholars.lib.ntu.edu.tw/handle/123456789/692839摘要：本計畫主要目的是使用微流體開發體外模擬血管動脈以及靜脈的血栓模型。利用此模型，用於分析奈米藥物載體治療血栓的效果。奈米載體主要使用Glycol chitosan (GCS)搭配conducting polymer (CP)作為載體。GCS同時具有兩親性 (bio-surfactant) 特性能夠做作為分散劑或穩定劑作為藥物傳輸系統。又GCS本身pKa大約6.5，因此在正常生理環境不帶電荷，而弱酸性情況下帶強正電的電荷轉換效應。此效應導致GCS在因為血栓而造成的弱酸環境下變成強電場而貼附於血栓上。CP因為具有光熱效應，可使用紅外光熱顯儀觀察材料貼附情形。因此，使用GCS-CP包覆的血栓溶解藥物(D)所形成的 GCS-CP-D，可以有效率的貼附於血栓上，並且釋放藥物溶解血栓。 本計畫預計使用三年的時間分別建立動脈血栓模型以及靜脈血栓模型，並分別分析先前開發的奈米藥物載體GCS-CP在攜帶血栓溶解藥物時，對於動脈血栓和靜脈血栓治療效果。以下為三年的大致上工作內容：第一年開發內皮細胞在靜態培養時候的血栓，同時調整GCS-CP-D的配方，調配具有不同濃度藥物的GCS-CP-D。並分析不同濃度的GCS-CP-D與血栓溶解的程度。第二年建立靜脈血管的血栓模型，並分析在穩定流場下不同濃度的GCS-CP-D貼附血栓與溶解血栓的能力。第三年建立動脈血管的血栓模型，包含脈衝流場以及收縮舒張的血管壁下，分析不同濃度的GCS-CP-D貼附血栓與溶解血栓的能力。<br> Abstract: The objective of this project is to develop an artery and a veins mimicking microfluidic platform with thrombosis. This platform can be used to test the thrombolytic drug carried by nanomedicine carrier, which is consisted of Glycol chitosan (GCS) and conducting polymer (CP). GCS is a bio-surfactant molecules that can be used as the dispersing agent and stabilizer in medicine transportation system. Further the pKa of the GCS is 6.5, so that the GCS is no charge in physiological system and positive charge in weak acidity. The charge transfer effect leads to that GCS can attach to inflamed cells which results to weak acid environment. Because of opto-thermal effect, the CP mixed GCS can be observed by infra-red thermographer. As the reason, the drug encapsulated GCS-CP, named GCS-CP-D, can efficiently attach to thrombosis clot and thus release drug. In this study, we propose a three-year proposal to establish the artery and the veins mimicking microfluidic platform with thrombosis. The ability of the thrombosis treatment of the nanomedicine carrier will be analyzed. The works of each year is listed below: First year, the thrombosis clog on endothelium will be developed. The protocol of the GCS-CP-D will be found, and the different ratio of the GCS-CP-D versus the ability of thrombosis dissolving will be investigated. Second year, the veins mimicking microfluidic platform with thrombosis will be established. The different ratio of the GCS-CP-D versus the ability of thrombosis dissolving will be investigated in a stable flow. Third year, the artery mimicking microfluidic platform with thrombosis will be established. The different ratio of the GCS-CP-D versus the ability of thrombosis dissolving will be investigated in the pulsatile flow and moving channel wall.微流體血栓奈米藥物載體內皮細胞Microfluidicsthrombosisnanomedicine carrierendothelial cell.